Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: Formulation design, in vitro and in vivo studies
Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh.
Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, Varanasi, Uttar Pradesh.
Antal upphovsmän: 32014 (Engelska)Ingår i: Hans Journal of Nanotechnology, ISSN 2161-086X, E-ISSN 2161-0878, Vol. 2014, artikel-id 351693Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The aim of the present work was to design and develop Praziquantal (PZQ) loaded solid lipid nanoparticles (PZQ-SLN) to improve the oral bioavailability by targeting intestinal lymphatic system. PZQ is practically insoluble in water and exhibits extensive hepatic first-pass metabolism. PZQ SLN were composed of triglycerides, lecithin and various aqueous surfactants; were optimized using hot homogenization followed by ultrasonication method. The optimized SLN had particle size of 123 ± 3.41 nm, EE of 86.6 ± 5.72 %. The drug release of PZQ-SLN showed initial burst release followed by the sustained release. Inspite of zeta potential being around -10 mV, the optimized SLN were stable at storage conditions (5 ± 3 °C and 25 ± 2°C/ 60 ± 5 % RH) for six months. TEM study confirmed the almost spherical shape similar to the control formulations. Solid state characterization using differential scanning calorimeter (DSC) and powder X-ray diffraction (PXRD) analysis confirmed the homogeneous distribution of PZQ within the lipid matrix. The 5.81-fold increase in AUC 0 → ∞, after intraduodenal administration of PZQ-SLN in rats treated with saline in comparison to rats treated with cycloheximide (a blocker of intestinal lymphatic pathway), confirmed its intestinal lymphatic delivery. The experimental results indicate that SLN may offer a promising strategy for improving the therapeutic efficacy and reducing the dose.

Ort, förlag, år, upplaga, sidor
2014. Vol. 2014, artikel-id 351693
Nationell ämneskategori
Annan hälsovetenskap
Forskningsämne
Hälsovetenskap
Identifikatorer
URN: urn:nbn:se:ltu:diva-62702DOI: 10.1155/2014/351693OAI: oai:DiVA.org:ltu-62702DiVA, id: diva2:1084884
Tillgänglig från: 2017-03-27 Skapad: 2017-03-27 Senast uppdaterad: 2018-04-11Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Rao Vuddanda, Parameswara

Sök vidare i DiVA

Av författaren/redaktören
Rao Vuddanda, Parameswara
I samma tidskrift
Hans Journal of Nanotechnology
Annan hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 9 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf